Cargando…

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

Bevacizumab is a humanized anti-vascular endothelial growth factor monoclonal antibody, used in combination with a oxaliplatin-based chemotherapy in the treatment of metastatic colorectal cancer (mCRC). The aim of the present study was to identify microRNA (miRNA)-based predictive biomarkers of ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiss, I., Mlčochová, J., Součková, K., Fabian, P., Poprach, A., Halamkova, J., Svoboda, M., Vyzula, R., Slaby, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494676/ https://www.ncbi.nlm.nih.gov/pubmed/28693229 http://dx.doi.org/10.3892/ol.2017.6255

Ejemplares similares

Identification and functional screening of microRNAs highly deregulated in colorectal cancer
por: Faltejskova, Petra, et al.
Publicado: (2012)

MicroRNAs in colorectal cancer: translation of molecular biology into clinical application
por: Slaby, Ondrej, et al.
Publicado: (2009)

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
por: Mlcochova, Jitka, et al.
Publicado: (2015)

Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer
por: Slaby, Ondrej, et al.
Publicado: (2012)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma
por: Mlcochova, Hana, et al.
Publicado: (2016)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2019)

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: Merhautova, Jana, et al.
Publicado: (2015)

Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX
por: Escalante, Paula I., et al.
Publicado: (2021)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy
por: Slaby, Ondrej, et al.
Publicado: (2010)

Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy
por: Slaby, Ondrej, et al.
Publicado: (2010)

MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications
por: Sana, Jiri, et al.
Publicado: (2011)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
por: Buchler, Tomas, et al.
Publicado: (2018)

Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
por: Otsu, Satoshi, et al.
Publicado: (2014)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2020)

MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
por: Svoboda, Marek, et al.
Publicado: (2012)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
por: Nemecek, Radim, et al.
Publicado: (2016)

Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
por: Redova, Martina, et al.
Publicado: (2012)

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
por: Wang, Feng, et al.
Publicado: (2022)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma
por: Fedorko, Michal, et al.
Publicado: (2017)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014)

The Impact of Diabetes Mellitus on the Second Primary Malignancies in Colorectal Cancer Patients
por: Halamkova, Jana, et al.
Publicado: (2021)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2017)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

Second primary malignancies in colorectal cancer patients
por: Halamkova, Jana, et al.
Publicado: (2021)

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
por: GRELL, PETER, et al.
Publicado: (2012)

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011)

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
por: Lakomy, Radek, et al.
Publicado: (2017)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
por: García‐Carbonero, Rocío, et al.
Publicado: (2017)

Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)

Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population
por: Hezova, Renata, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_01ha3fupbg0hrcjgo99pi3hhp8